Navigation Links
New Peripheral Vascular Device Market Research Data Covering Multiple Geographies Released by Millennium Research Group
Date:11/15/2010

r further details.

About Millennium Research GroupMillennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer behavior tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Amy KrohnMillennium Research Group416-364-7776 ext. 101akrohn@mrg.netChris ComfortDecision Resources, Inc. 781-993-2597ccomfort@dresources.com
'/>"/>

SOURCE Millennium Research Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pfizers Lyrica® (Pregabalin) Capsules CV Receives Approval for Treatment of Peripheral Neuropathic Pain In Japan
2. U.S. Market for Peripheral Vascular Devices 2010 now Available at ReportsandReports
3. Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years
4. Japanese Peripheral Vascular Stent Procedures to Experience 11% Growth Through 2014
5. IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERipheral Stent
6. Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 2013
7. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent
8. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
9. Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series
10. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
11. Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015 /PRNewswire/ – Small Cap IR issues ... to supply custom Arrayit blood card technology to Vivos, ... on earth. Vivos offers an impervious, impenetrable and permanent ... woman and child on Earth, a safe and secure ... blood cards allow the rapid collection, separation, drying and ...
(Date:6/30/2015)... 30, 2015  Egalet Corporation (Nasdaq: ... pharmaceutical company focused on developing, manufacturing and ... results from a Category 3 human abuse ... extended-release, oral oxycodone product candidate in late-stage ... severe enough to require daily, around-the-clock opioid ...
(Date:6/30/2015)... 30, 2015 PharmaVentures is pleased ... Chip-Man Technologies Oy (CMT) on its divestment of certain ... to CMTs world leading capabilities in cellular imaging and ... a series of successful global deals in the life ... Fintan Walton , CEO, PharmaVentures, commented: "PharmaVentures is ...
Breaking Medicine Technology:Small Cap IR - Empowering the Age of Genetic Enlightenment 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5PharmaVentures Completes M&A Deal for Technology in the Stem Cell & Regenerative Medicine Sector 2
... SAN DIEGO, May 5, 2011 /PRNewswire/ -- Halozyme ... developing and commercializing products targeting the extracellular matrix , ... of America Merrill Lynch Health Care Conference in Las Vegas. ... PDT (2:10 p.m. EDT). To listen to the live webcast ...
... 2011 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... 31, 2011.  Savient ended the quarter with $268.0 million in ... December 31, 2010, primarily due to the issuance and sale ... the first quarter of 2011, the Company had a net ...
Cached Medicine Technology:Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12 2Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 2Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 3Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 4Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 5Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 6Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 7
(Date:7/1/2015)... ... 2015 , ... Nutritional Products International, a brand focused on the global marketing ... 2015 ECRM Diet, Vitamin & Sports Nutrition conference in Tampa, Florida, where it made ... trade show allows companies the chance to meet with a variety of the most ...
(Date:7/1/2015)... ... , ... Recent research has revealed that most adults lack confidence in the ... professionals. Starting the last Monday of June, Whiter Image Dental will help ... on the customer’s first popular In-Office 2 Patient Kit. , The ...
(Date:7/1/2015)... ... July 01, 2015 , ... Effective June 9, 2015, the Radiology Business ... The annual board election process has been in place since the RBMA was founded ... Suzanne Taylor, BS, FRBMA, succeeds Keith E. Chew, MHA, CMPE, as president. Ms. Taylor ...
(Date:6/30/2015)... ... ... In the Spring of 2015, as California imposed unprecedented water-use restrictions on its cities ... first time since records have been kept, the New York Times reported that “the ... drought.” , In response to the potentially devastating effects of these current ...
(Date:6/30/2015)... PA (PRWEB) , ... June 30, 2015 , ... America ... by cardiovascular disease, cancer, autism, dementia, auto-immune deficiencies, or obesity. Why? , The answer ... , Dr. Pete Sulack, America’s Leading Stress Expert, has successfully treated over one million ...
Breaking Medicine News(10 mins):Health News:NPI Meets With Top Retail Figures at ECRM Conference 2Health News:Whiter Image Dental Offers New Customers Half-Off Teeth Whitening Kit 2Health News:Radiology Business Management Association Announces Board of Directors and Officers for 2015-2016 2Health News:Radiology Business Management Association Announces Board of Directors and Officers for 2015-2016 3Health News:Radiology Business Management Association Announces Board of Directors and Officers for 2015-2016 4Health News:RainSoil launches water-retention product as drought spreads. 2Health News:RainSoil launches water-retention product as drought spreads. 3Health News:12 Easy-To-Follow Steps to Transform Body, Mind and Spirit 2
... 3 Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ) today ... will provide a corporate,overview at the upcoming Collins Stewart ... July 8, 2008 in New York, NY., Interested ... visiting,the Sunesis website at http://ir.sunesis.com . A replay ...
... Rigel Pharmaceuticals,Inc. (Nasdaq: RIGL ) today announced that ... will present a company overview,at the Fourth Annual Collins ... a.m. EDT at The Mandarin Oriental Hotel in New ... or the subsequent archived recording,log on to http://www.rigel.com ...
... 2 The Michigan Attorney General announced,on July 2 ... Shield of,Michigan challenging a capital transaction between BCBSM and ... position that BCBSM is not,authorized by Public Act 350 ... Accident Fund obtained prior regulatory approval for the,transaction. BCBSM ...
... has spread to distant sites has a poor prognosis, but ... slow disease progression in some patients, a research team led ... Cancer Center reports in the July 3rd edition of ... drug, motesanib diphosphate, is a VEGF inhibitor, a biologic agent ...
... 2 A Miami resident was,sentenced to 130 months ... the,Medicare program, Acting Assistant Attorney General Matthew Friedrich of,the ... the Southern,District of Florida announced today., Gustavo Smith, ... for,the Southern District of Florida by Judge Marcia G. ...
... Hanger Orthopedic,Group, Inc. (NYSE: HGR ) ... Services revised its outlook for Hanger Orthopedic Group, ... corporate credit,rating at "B." "The outlook revision reflects ... improved financial risk profile," said,Standard & Poor,s credit ...
Cached Medicine News:Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 2Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 3Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 4Health News:Owner of Medical Equipment Company Sentenced to 130 Months in Prison for Health Care Fraud 2Health News:Owner of Medical Equipment Company Sentenced to 130 Months in Prison for Health Care Fraud 3Health News:Hanger Orthopedic Group, Inc. Receives Positive Outlook from Standard & Poor's Rating Services 2
Designed to be removed from under surgical gown without compromising sterile fields. Two straps criss-cross in the back and attach with velcro in the front....
Wolfs unique apron and vest set distributes weight evenly between shoulders and hips. The vest comes with an attached Thyroid collar...
... Full frontal protection, our conventional ... shoulders by sturdy 2 webbed ... quick-acting snap hook fasteners. The ... custom fit the apron. Our ...
... Aprons are the result of a technologically ... x-ray aprons. Constructed with a wear resistant, ... the Lead Free aprons exhibit the same ... Each apron weighs approximately 50% less than ...
Medicine Products: